Nymox Pharma: Up on long-term safety data of lead drug

Nymox Pharmaceutical

03/10/2018 18:16

** Drug developer's shares  NYMX.O  up ~10 pct at $2.57 
    ** Co says long-term safety assessments identified no
serious side effects related to its lead drug for treating
prostate cancer and prostate enlargement  urn:newsml:reuters.com:*:nGNXZ4sH2
    ** Co conducted 2 safety studies during 2010-2014 involving
351 patients with prostate enlargement, who were subsequently
assessed for up to 7 yrs
    ** Drug has been in development for over 10 yrs and has
shown clinically meaningful relief in lower urinary tract
symptoms associated with prostate enlargement, a problem that
affects ~100 mln men globally
    ** Drug also being developed to treat prostate cancer 
    ** Co seeks U.S. and EU marketing approvals for treating
prostate enlargement
    ** More than 406k shares traded, ~5.5x times their 25-day
moving avg.
    ** Despite Wednesday's early gains, stock still down 22 pct
this year

 (Reporting by Saumya Sibi Joseph in Bengaluru)
 ((Reuters Messaging:
saumya.joseph.thomsonreuters.com@reuters.net))